Abstract:Considerable evidence is mounting that dyshomeostasis of the redox-active biometals, Cu and Fe, and oxidative stress contribute to the neuropathology of Alzheimer's disease (AD). Present data suggest that metals can interact directly with Abeta peptide, the principal component of beta-amyloid that is one of the primary lesions in AD. The binding of metals to Abeta modulates several physiochemical properties of Abeta that are thought to be central to the pathogenicity of the peptide. First, We and others have shown that metals can promote the in vitro aggregation into tinctorial Abeta amyloid. Studies have confirmed that insoluble amyloid plaques in postmortem AD brain are abnormally enriched in Cu, Fe, and Zn. Conversely, metal chelators dissolve these proteinaceous deposits from postmortem AD brain tissue and attenuate cerebral Abeta amyloid burden in APP transgenic mouse models of AD. Second, we have demonstrated that redox-active Cu(II) and, to a lesser extent, Fe(III) are reduced in the presence of Abeta with concomitant production of reactive oxygen species (ROS), hydrogen peroxide (H2O2) and hydroxyl radical (OH.). These Abeta/metal redox reactions, which are silenced by redox-inert Zn(II), but exacerbated by biological reducing agents, may lead directly to the widespread oxidation damages observed in AD brains. Moreover, studies have also shown that H2O2 mediates Abeta cellular toxicity and increases the production of both Abeta and amyloid precursor protein (APP). Third, the 5' untranslated region (5'UTR) of APP mRNA has a functional iron-response element (IRE), which is consistent with biochemical evidence that APP is a redox-active metalloprotein. Hence, the redox interactions between Abeta, APP, and metals may be at the heart of a pathological positive feedback system wherein Abeta amyloidosis and oxidative stress promote each other. The emergence of redox-active metals as key players in AD pathogenesis strongly argues that amyloid-specific metal-complexing agents and antioxidants be investigated as possible disease-modifying agents for treating this horrible disease.

Effects of Redox Homeostasis and Mitochondrial Damage on Alzheimer's Disease

Redox imbalance and metabolic defects in the context of Alzheimer disease

Redox changes and cellular senescence in Alzheimer's disease

Mitochondrial Dysfunction in Microglia: a Novel Perspective for Pathogenesis of Alzheimer’s Disease

Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease

Oxidative stress and the pathogenesis of Alzheimer's disease.

Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease

Redox Signaling and Alzheimer’s Disease: from Pathomechanism Insights to Biomarker Discovery and Therapy Strategy

Molecular mechanisms of mitochondrial homeostasis regulation in neurons and possible therapeutic approaches for Alzheimer's disease

Alzheimer Disease: Recent Updates on Apolipoprotein E and Gut Microbiome Mediation of Oxidative Stress, and Prospective Interventional Agents.

Free radicals in Alzheimer's disease: From pathophysiology to clinical trial results

Redox-active metals, oxidative stress, and Alzheimer's disease pathology.

Recent Advances of Mitochondrial Alterations in Alzheimer's Disease: A Perspective of Mitochondrial Basic Events

A Mitocentric View of Alzheimer’s Disease

Mitochondria in Alzheimer's Disease Pathogenesis

Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances

Mitochondrial Dysfunction: Common Final Pathway in Brain Aging and Alzheimer’s Disease—Therapeutic Aspects

Targeting Mitochondrial Dysfunction and Reactive Oxygen Species for Neurodegenerative Disease Treatment

Oxidative stress‐A direct bridge to central nervous system homeostatic dysfunction and Alzheimer's disease

Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer's Disease Pathogenesis

Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity